Carl Zeiss Meditec AG and PhysIOL SA settle legal dispute

Jena, 18.08.2014.

PhysIOL SA and Carl Zeiss Meditec AG have settled their legal dispute about patents and utility models for trifocal intraocular lenses (IOL) out of court. Under a Settlement agreement, the two parties have agreed to permit the unrestricted distribution of products from the FINEVISION line (PhysIOL SA) and AT LISA tri line (Carl Zeiss Meditec AG) as well as products based on this technology. Contrary to a statement made in an earlier press release by PhysIOL SA in the course of the proceedings, PhysIOL SA recognized IP rights held by Carl Zeiss Meditec AG and therefore accepted entering into an agreement with Carl Zeiss Meditec AG. Carl Zeiss Meditec AG does not make any payments to PhysIOL SA under the agreement. The information comes from both companies.

The agreement extends not only to markets protected directly by industrial property rights such as Germany, the USA and Japan, but also regions that will be covered by future rights. The agreement applies with immediate effect. Both companies have undertaken to withdraw all infringement suits, patent opposition proceedings and a cancellation request for a utility model. The specific terms of the settlement are confidential.
Intraocular lenses (IOL) are used primarily in the treatment of cataract. The development of innovative new lenses has significantly improved opportunities for treatment over the past few years. Trifocal intraocular lenses allow suitable patients good vision over all distances - in many cases, not even eyeglasses are required.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.